Conditions: Mild Intermittent Asthma
Keywords: late allergic response fluticasone propionate
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 7
Healthy volunteers: no

Brief summary:
The investigators propose a 3-treatment, placebo-controlled, double-dummy, double-blinded, randomized, crossover study in which single doses of placebo, will be compared to Fluticasone propionate (Flovent Diskus) 250 mcg and budesonide 400 mcg administered after allergen challenge, at cessation of the early allergic reaction (at 20% fall in FEV1 from post-allergen peak)

Detailed description:
The aim of this pilot study is to evaluate whether fluticasone propionate affects the late allergic reaction after a single dose post-allergen challenge administered following cessation of the early allergic reaction.

Six subjects with mild asthma will be asked to volunteer for the study.The diagnosis of asthma will be and includes the presence of variable airflow limitation and AHR (PC20 methacholine \< 16 mg/mL). Subjects will be asked to participate if they demonstrate an allergen-induced early and late asthmatic response of at least 20% and 15% reduction in FEV1, respectively.

The study will consist of 4 periods, composed of a screening allergen period with 3 subsequent allergen challenge/treatment periods. Each period will be separated with a washout of at least 2 weeks. Subjects who demonstrate a dual asthmatic response in the screening period will be selected for randomization to treatment.

Arms:
arm 1: Fluticasone propionate (Flovent Diskus) 250 mcg arm 2: budesonide 400mcg arm 3: placebo

Interventions: intervention 1: Fluticasone propionate (Flovent Diskus) 250 mcg intervention 2: budesonide 400 mcg intervention 3: Placebo
Intervention descriptions: intervention 1: Flovent Diskus 250 mcg intervention 2: budesonide 400 mcg intervention 3: Placebo

Protocol document: